Home
About
Overview
Sharing Data
ORCID
Help
History (16)
Medical management of perianal Crohn's disease.
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
See All 16 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal
Anti-Inflammatory Agents
Colectomy
Colitis, Ulcerative
Double-Blind Method
Drug Administration Schedule
Europe
Female
Gastrointestinal Agents
Hospitalization
Humans
Infliximab
Injections, Intravenous
Kaplan-Meier Estimate
Male
Middle Aged
North America
Proportional Hazards Models
Risk Assessment
Severity of Illness Index
Time Factors
Treatment Outcome
authors with profiles
Stephen B. Hanauer